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Abstract
ProSAAS is the precursor of a number of peptides that have been proposed to function as neuropeptides. Because proSAAS
mRNA is highly expressed in the arcuate nucleus of the hypothalamus, we examined the cellular localization of several
proSAAS-derived peptides in the mouse hypothalamus and found that they generally colocalized with neuropeptide Y
(NPY), but not a-melanocyte stimulating hormone. However, unlike proNPY mRNA, which is upregulated by food
deprivation in the mediobasal hypothalamus, neither proSAAS mRNA nor proSAAS-derived peptides were significantly
altered by 1–2 days of food deprivation in wild-type mice. Furthermore, while proSAAS mRNA levels in the mediobasal
hypothalamus were significantly lower in Cpe
fat/fat mice as compared to wild-type littermates, proNPY mRNA levels in the
mediobasal hypothalamus and in other subregions of the hypothalamus were not significantly different between wild-type
and Cpe
fat/fat mice. Intracerebroventricular injections of antibodies to two proSAAS-derived peptides (big LEN and PEN)
significantly reduced food intake in fasted mice, while injections of antibodies to two other proSAAS-derived peptides (little
LEN and little SAAS) did not. Whole-cell patch clamp recordings of parvocellular neurons in the hypothalamic
paraventricular nucleus, a target of arcuate NPY projections, showed that big LEN produced a rapid and reversible inhibition
of synaptic glutamate release that was spike independent and abolished by blocking postsynaptic G protein activity,
suggesting the involvement of a postsynaptic G protein-coupled receptor and the release of a retrograde synaptic
messenger. Taken together with previous studies, these findings support a role for proSAAS-derived peptides such as big
LEN as neuropeptides regulating food intake.
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Introduction
Peptides play major roles in diverse physiological functions,
including as hormones, neurotransmitters, and growth factors
[1,2]. Bioactive peptides are typically produced by cleavage of
larger precursor proteins at specific sites containing basic residues,
often in pairs such as Arg-Arg or Lys-Arg [3,4]. Endopeptidases
such as prohormone convertase (PC) 1/3 and 2 cut the precursors
at these sites, generating intermediate peptides with C-terminal
basic amino acid extensions [5,6]. Carboxypeptidases then trim
these basic residues from the ends of the peptides, after which the
peptides may need further modification (such as amidation) before
the peptides are biologically active [7]. Carboxypeptidase E (CPE)
is the major peptide-processing carboxypeptidase; this enzyme is
found in all neuroendocrine tissues and cleaves many C-terminally
extended peptides to generate the mature bioactive form [8]. The
fat mutation, a spontaneous mouse mutation, was found to be a
point mutation in CPE that causes the peptidase to be inactive [9].
Mice homozygous for this mutation, which was renamed Cpe
fat,
show an accumulation of the peptide processing intermediates
containing basic residues on their C-termini and a reduction in
levels of fully processed peptides [10]. An affinity chromatography
technique was used to isolate these neuropeptide intermediates
after which the peptides were sequenced using tandem mass
spectrometry [11]. This approach identified the processing
intermediates of many previously characterized neuroendocrine
peptides as well as several novel peptides. Five of these novel
peptides were named based on primary amino acid sequences
contained within the larger peptides: big SAAS, little SAAS, PEN,
big LEN, and little LEN. All five of these peptides were derived
from the same precursor, named proSAAS, by cleavage at basic
amino acid-containing sites (Figure 1). The involvement of CPE in
the biosynthesis of proSAAS-derived peptides indicates that these
peptides are processed in the regulated secretory pathway of
neuroendocrine cells.
Although there is no sequence similarity among proSAAS and
other proteins, there are some features in common between
proSAAS and 7B2, a member of the granin family [12]. Both
proteins are broadly expressed in brain and neuroendocrine tissues
[13], are generally the same size, and contain multiple cleavage
sites for the PCs and CPE [11,12,14]. 7B2 is an inhibitor of PC2
[15,16]. Similar studies with proSAAS showed that a small region
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inhibitor of PC1/3, but neither PEN nor LEN were able to inhibit
PC1/3 [17]. Therefore, PEN, LEN, and peptides cleaved from the
N-terminal region of proSAAS may serve other functions.
ProSAAS is present in neuroendocrine cells lacking PC1/3,
further suggesting that proSAAS-derived peptides may have
functions independent of the role of proSAAS as a PC1/3
inhibitor [14].
Levels of proSAAS mRNA are highest in brain regions involved
in feeding and body weight regulation, such as the arcuate nucleus
and other regions of the hypothalamus [11]. Semi-quantitative in
situ hybridization analysis of proSAAS mRNA in the Allen Mouse
Brain Atlas shows highest levels in the arcuate nucleus (Figure S1).
The pattern of proSAAS mRNA distribution in the medial
hypothalamus is very similar to that of mRNAs encoding peptides
known to function in body weight regulation, such as neuropeptide
Y (NPY) and a-melanocyte stimulating hormone (a-MSH); the
pattern of proSAAS mRNA distribution is distinct from that of
PC1/3 mRNA (Figure 1). Transgenic mice overexpressing
proSAAS showed a significant, late-onset gain in bodyweight,
yet processing of peptides by PC1/3 appears normal in these mice,
suggesting that the effect on bodyweight is not due to the
inhibitory action of proSAAS and consistent with the possibility
that the fully processed proSAAS-derived peptides have an
orexigenic effect [18]. Furthermore, male mice lacking proSAAS
show a 10–15% decrease in bodyweight, further suggesting that
proSAAS-derived peptides have orexigenic effects [19]. Additional
evidence that proSAAS-derived peptides function in body weight
regulation was the finding that Cpe
fat/fat mice have elevated levels of
big LEN, relative to wild-type littermates [20]. Also, when Cpe
fat/fat
mice were deprived of food for 48 hours, the levels of several
proSAAS-derived peptides increased several fold [21]. Taken
together, these studies suggest a role for proSAAS-derived peptides
in the control of body weight.
In the present study, we first examined if proSAAS-derived
peptides colocalize with a-MSH or NPY in the arcuate nucleus
using fluorescent double labeling immunohistochemistry. NPY is a
well characterized orexigenic neuropeptide, whereas a-MSH is an
established anorexigenic neuropeptide, both of which are
expressed in distinct neurons of the hypothalamus. We also
examined if proSAAS-derived peptides colocalized with green
fluorescent protein (GFP) expressed under an NPY neuronal
promoter. Because previous studies showed that proSAAS
peptides were up-regulated in Cpe
fat/fat mice, relative to wild-type
mice, and further elevated in Cpe
fat/fat mice subjected to food
deprivation, we examined if levels of proSAAS mRNA and/or
peptides were altered under these conditions. We also examined if
intracerebroventricular (icv) injection of proSAAS-derived pep-
tides or antibodies to these peptides affected food intake of mice.
Previous studies established the orexigenic role of NPY by showing
Figure 1. Schematic of proSAAS and proSAAS-derived peptides, and the localization of proSAAS, proNPY, POMC, and PC1/3 mRNA
in the hypothalamus of the mouse. Top panel: Schematic diagram showing the major proSAAS-derived peptides previously detected in various
brain regions and other relevant peptides. The relative size and position of these peptides within proSAAS are indicated. Bottom panels: Images of
proSAAS, proNPY, POMC, and PC1/3 mRNA distribution were downloaded from the Allen Mouse Brain Atlas [http://mouse.brain-map.org], Seattle,
WA, Allen Institute for Brain Science 2009 [50].
doi:10.1371/journal.pone.0028152.g001
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whereas injection of anti-NPY antibodies reduced food intake
[22,23,24]. A direct role for big LEN as a neuropeptide was
further explored using whole-cell patch clamp recording of
neurons located in the medial parvocellular region of the
paraventricular nucleus. Because the paraventricular parvocellular
neurons receive input from NPY-expressing neurons [25], these
neurons should also be exposed to big LEN in vivo based on the
general colocalization of big LEN and NPY. Taken together with
previous studies, our results suggest that big LEN is a neuropeptide
that functions in the control of food intake.
Results
Colocalization of proSAAS-derived peptides with NPY
The Allen Mouse Brain Atlas shows the highest levels of
proSAAS mRNA in the hypothalamus, specifically concentrated
in the area of the arcuate nucleus (Figure 1 and Figure S1). This
distribution pattern is similar to the distribution of mRNAs
encoding NPY and proopiomelanocortin (POMC), the precursor
of a-MSH (Figure 1). To test whether proSAAS-derived peptides
colocalized with either NPY or a-MSH at the cellular level, we
performed double immunofluorescence analyses with antisera to
NPY, a-MSH, PEN-LEN, PEN and LEN. A chicken antiserum to
the proSAAS peptide PEN-LEN and rabbit antisera to the
peptides PEN and LEN were used together with commercially
available antisera to NPY (rabbit) and a-MSH (sheep). PEN-LEN
immunoreactivity was found throughout the mouse brain, with
highest levels in the arcuate nucleus. A punctate staining pattern
for PEN-LEN in the hypothalamic cell bodies suggested vesicular
localization of these peptides (Figure 2). Co-staining of these same
brain sections with an antibody against NPY showed strong
immunoreactivity in the hypothalamus, also concentrated in the
arcuate nucleus. When merged, images of the arcuate nucleus
immunostained for both PEN-LEN and NPY showed considerable
colocalization of these two peptides (Figure 2). These results
indicate that some cells in the hypothalamus produce both
proSAAS-derived peptides and NPY. In contrast, no overlap was
observed when the arcuate nucleus was co-stained with a-MSH
and either PEN-LEN or big LEN (Figure 2). The chicken anti-
PEN-LEN antiserum showed extensive overlap with rabbit
antisera to both big LEN (Figure 2) and PEN (not shown), as
expected. The LEN antiserum used in these experiments was
previously shown to be specific for big LEN and not recognize
little LEN peptide, which lacks six C-terminal amino acids [26].
To confirm this, we performed blocking experiments and found
that when the LEN antiserum was preincubated with big LEN
peptide, there was a substantial decrease in immunofluorescence
whereas similar experiments with little LEN peptide did not
reduce the signal (Figure S2). Additional controls with preimmune
serum showed negligible signals (Figure S2).
ProSAAS- derived peptides in NPY peptidergic neurons
To directly test if immunoreactive PEN and big LEN colocalize
with NPY-expressing neurons, we examined brain sections from
mice expressing green fluorescent protein (GFP) under control of
the NPY neuronal promoter. These mice show strong GFP
fluorescence in the cell bodies of NPY neuropeptidergic neurons in
the arcuate nucleus of the hypothalamus [27]. Many of these GFP-
positive cells were positive for the expression of big LEN and PEN
(Figure 3). Both big LEN and PEN immunoreactivity appeared
with a punctate distribution, consistent with localization to
secretory vesicles, while GFP under the control of the NPY
promoter was expressed in the cytosol. Only low levels of
background staining were observed when using preimmune serum
(Figure 3).
Quantitative real-time PCR (qRTPCR) in subhypothalamic
brain regions
The finding that proSAAS-derived peptides and NPY are
colocalized in many neurons raised the question of whether
proSAAS and NPY are co-regulated. Previously, mRNA encoding
NPY has been shown to be up-regulated by food deprivation [28].
Furthermore, in Cpe
fat/fat mice, food deprivation was found to
increase several proSAAS-derived peptide processing intermedi-
ates [21]. In addition, the C-terminal proSAAS peptide big LEN
was found to be several-fold more abundant in Cpe
fat/fat mouse
hypothalamus compared to wild-type mouse hypothalamus [20].
Thus, we developed probes to detect proSAAS mRNA using
qRTPCR so that analysis of mRNA levels could be performed in
subregions of the hypothalamus. Probes for qRTPCR analysis of
mouse proNPY mRNA were used to compare with the proSAAS
mRNA.
Relative levels of proSAAS and proNPY mRNA were
quantified in the paraventricular nucleus (PVN), the lateral
Figure 2. Coronal sections through mouse hypothalamus
showing immunofluorescence colocalization of peptides in
the arcuate nucleus. The upper panels show immunoreactive PEN/
LEN peptides in red and immunoreactive big LEN peptides in green. The
merged images (right) show general colocalization of the two peptides.
The panels in the second row show immunoreactive PEN/LEN peptides
in red and immunoreactive NPY peptides in green, and merged images
show essentially complete colocalization of the two peptides. The
panels in the third row show immunoreactive PEN/LEN peptides in red
and immunoreactive a-MSH peptides in green. Merged images show no
colocalization of the two peptides. The bottom row shows immuno-
reactive big LEN peptides in red and immunoreactive a-MSH peptides
in green. Merged images show no colocalization of the two peptides.
Nuclei are stained blue using DAPI (4,6- diamidino-2-phenylindole). The
scale bar indicates 10 mm.
doi:10.1371/journal.pone.0028152.g002
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which includes the arcuate nucleus. The level of proSAAS mRNA
was highest in the MBH, and slightly lower in the PVN and LH
(Figure 4). These results generally match the distribution of
proSAAS mRNA by in situ hybridization (Figure 1), considering
that the MBH contains other regions in addition to the arcuate
nucleus. ProNPY mRNA was much higher in the MBH than the
other brain regions examined (Figure 4), consistent with the in situ
hybridization results for this mRNA (Figure 1).
To test if the previously observed elevated levels of big LEN in
Cpe
fat/fat mouse hypothalamus, relative to wild-type mouse
hypothalamus [20], was due to increased proSAAS mRNA levels,
qRTPCR analysis was used to compare Cpe
fat/fat and wild-type
mice. Surprisingly, levels of proSAAS mRNA decreased in the
MBH and LH of Cpe
fat/fat mice, relative to wild-type mice,
although this difference was only statistically significant in the
MBH (Figure 5A). Therefore, the 2-fold increase in big LEN
previously observed in the Cpe
fat/fat mouse hypothalamus is not due
to an increase in proSAAS mRNA levels. ProNPY mRNA was
also compared between Cpe
fat/fat and wild-type mice and found to
show a tendency to decrease in the MBH of Cpe
fat/fat mice,
although this change was not statistically significant (Figure 5B). In
addition, proNPY mRNA showed a tendency to decrease in the
LH of Cpe
fat/fat mice, but this change was not statistically significant
(Figure 5B).
To explore whether proSAAS and proNPY mRNA are co-
regulated upon food deprivation, mice were fasted for 48 hours,
mRNA was extracted from the hypothalamic subregions, and
qRTPCR was performed. ProSAAS mRNA was not greatly
affected by food deprivation in any hypothalamic region analyzed
of WT mice (Figure 6A), whereas proNPY mRNA was
significantly elevated, by approximately 150%, in the MBH of
the food-deprived WT mice (Figure 6B). The increase in proNPY
mRNA in the MBH is consistent with a previous report [28].
Because proSAAS-derived peptides were previously found to be
elevated by food deprivation in Cpe
fat/fat mice, we examined if
proSAAS mRNA levels were affected by fasting in the mutant
animals. As found for the WT mice, proSAAS mRNA levels were
not greatly altered by food deprivation in the MBH or other
hypothalamic regions in the Cpe
fat/fat mice (Figure 6C). Levels of
proNPY mRNA increased significantly in the MBH of the fasted
Cpe
fat/fat mice, but were not altered in other subhypothalamic brain
regions (Figure 6D).
Peptidomic analysis of proSAAS-derived peptide levels in
fed and fasted wild-type mice
The previous study that found that food deprivation led to
elevated levels of proSAAS-derived peptides was performed in
Cpe
fat/fat mice and examined peptide processing intermediates, not
the mature forms of the peptides [21]. To test if food deprivation
affected levels of the mature forms of the peptides in wild-type
mice, relative levels of proSAAS-derived peptides were quantified
using a mass spectrometry-based quantitative peptidomics tech-
nique. Peptide levels from the hypothalami of wild-type mice fed
ad libitum were compared to levels in mice fasted for either 24 or
48 hours. Several peptides derived from proSAAS were detected
in this analysis, including big LEN, little SAAS, PEN, and several
smaller fragments of little SAAS and PEN (Table 1). None of these
peptides showed a significant change between fed animals and
either of the food-deprived groups (Table 1).
Injection of proSAAS-derived peptides in mouse
hypothalamus; effects on acute food intake
The colocalization of proSAAS peptides with the orexigenic
peptide NPY, as well as the phenotypes of proSAAS transgenic
and proSAAS knockout mice [18,19], indicate a possible
orexigenic role for proSAAS-derived peptides. In order to test
the effects of these peptides on food intake, we injected mice in the
third ventricle with 10 mg of either PEN, big LEN, little SAAS, or
a combination of PEN and big LEN peptides. Food intake was
measured at 1, 2 and 14 hours post injection and compared to
food intake in saline-injected control mice. None of the proSAAS-
derived peptides showed a significant effect on food intake at any
of the recorded time points (Figure 7).
Figure 3. Coronal sections through the hypothalamus of NPY-
GFP mice showing immunofluorescence localization of pep-
tides in the arcuate nucleus. The upper panel shows immunoreac-
tive big LEN peptides in red and NPY neurons expressing GFP in the
cytosol in green. In the merged images big LEN peptide immunore-
activity can be seen in the green GFP-expressing neurons. The middle
row of panels shows immunoreactive PEN peptides in red and NPY
neurons in green. In the merged images, PEN peptide immunoreactivity
can be seen in the green GFP-expressing neurons. The bottom panels
show a section incubated with pre-immune serum and secondary Cy3
antibodies, with background staining only. Nuclei are stained blue
using DAPI (4,6- diamidino-2-phenylindole). Scale bar 10 mm.
doi:10.1371/journal.pone.0028152.g003
Figure 4. Levels of proSAAS mRNA and proNPY mRNA in
subhypothalamic brain regions. Left: ProSAAS mRNA in the MBH,
PVN, and LH in wild-type mice. Right: The MBH expresses the highest
levels of proNPY mRNA, while the PVN and LH express much lower
levels. Error bars show standard error of the mean (n=8).
doi:10.1371/journal.pone.0028152.g004
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fat/fat mice. A: proSAAS mRNA
levels are significantly lower (p=0.041) in the MBH of the Cpe
fat/fat mice, relative to wild-type (WT) mice, and show a tendency to decrease in the LH of
the Cpe
fat/fat mice, but in this brain region the difference is not statistically significant (p=0.23). B: proNPY mRNA levels show a tendency to decrease
in the MBH and LH of Cpe
fat/fat mice, relative to wild-type mice, but these changes are not statistically significant (p=0.17 and 0.19, respectively). Error
bars show standard error of the mean for n=8. Abbreviations: WT, wild-type; fat/fat, Cpe
fat/fat.* ,p ,0.05 using Student’s two-tailed t-test.
doi:10.1371/journal.pone.0028152.g005
Figure 6. Comparison of proSAAS mRNA and proNPY mRNA levels in fed and fasted mice in various subhypothalamic brain
regions. A. ProSAAS mRNA levels do not show a significant change in fasted WT mice relative to mice fed ad libitum in any of the brain regions
examined. B. ProNPY mRNA levels increase significantly in the MBH of fasted mice relative to fed mice, but are not affected in the other two brain
regions examined. C. ProSAAS mRNA levels do not show a significant change with fasting in subhypothalamic brain regions of Cpe
fat/fat mice. D.
ProNPY mRNA is significantly increased in the MBH of fasted Cpe
fat/fat mice. Error bars show standard error of the mean for n=8 in WT mice and n=3
in Cpe
fat/fat mice. *, p,0.05 using Student’s two-tailed t-test.
doi:10.1371/journal.pone.0028152.g006
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in mouse hypothalamus; effects on food intake
Because the proSAAS-derived peptides may not be stable upon
icv injection into mouse brain, we tested whether icv injections of
purified antibodies directed against the proSAAS peptides PEN,
big LEN, little LEN and little SAAS affected food intake. At the
one-hour time point, there was a significant decrease in food
intake for mice injected with antibodies directed against PEN and
big LEN (Figure 8). These mice ate approximately 50% as much
as mice injected with saline or with a control antibody raised
against a region of a Drosophila protein which has no counterpart in
mammals. In contrast to the results with the antibodies to PEN
and big LEN, there was no effect on food intake in mice injected
with an antibody to little LEN. Mice injected with the antibody to
little SAAS showed a small but significant increase in food intake
relative to control antibody, although this increase was not
significant compared to the saline injection (Figure 8). At the two
hour time point, both PEN and big LEN antibodies continued to
exert their anorexigenic effects, as these mice ate significantly less
than mice injected with control antibody or saline (Figure 8). In
contrast, mice injected with the little SAAS antibody showed no
significant difference compared to the control group at the 2 hour
time point. The effect of the PEN antibody on food intake was still
observed after 14 hours, whereas mice injected with the antibody
to big LEN returned to normal eating levels relative to controls by
this time point.
Electrophysiological analyses
Together with previous studies, the results described above
suggest that proSAAS peptides PEN and big LEN function as
neuropeptides. To explore this in more detail, we focused on big
LEN using whole-cell patch clamp recordings in neurons located
Table 1. Relative levels of proSAAS-derived peptides in fed and fasted mice.
Peptide name Sequence Theor. Mass n Cont A/B= 1 d fast/Cont 2 d fast/Cont
Avg ± SD Avg ± SD Avg ± SD
Big LEN LENPSPQAPARRLLPP 1754.98 4 0.9860.06 0.9760.13 1.0660.06
Little SAAS SLSAASAPLVETSTPLRL 1812.01 4 1.0860.15 1.0760.28 1.0760.16
Little SAAS 1–16 SLSAASAPLVETSTPL 1542.81 4 1.0560.13 0.9660.15 1.0660.20
Little SAAS 5–18 ASAPLVETSTPLRL 1453.81 2 1.1260.01 1.0960.09 1.0360.21
PEN SVDQDLGPEVPPENVLGALLRV 2316.23 4 0.9560.12 0.9660.15 1.0260.26
PEN-18 (SVDQDLGPEVPPENVLGA) 1834.90 4 0.9060.10 0.9860.24 1.0260.14
PEN-19 (SVDQDLGPEVPPENVLGAL) 1947.98 4 1.0760.19 0.9660.13 1.0060.21
PEN-20 SVDQDLGPEVPPENVLGALL 2061.06 4 0.9360.09 0.9560.21 1.0560.24
Abbreviations: Theor. Mass, theoretical monoisotopic mass of the peptide without isotopic tags or protons; n, number of runs in which the peptide was detected;
Cont A/B, the relative level of peptide in two distinct groups of mice fed ad libitum; 1 d fast/Cont, the relative level of peptide in mice fasted for 1 day, relative to the
level in control group B; 2 d fast/Cont, the relative level of peptide in mice fasted for 2 days, relative to control group B; Avg 6 SD, average ratio of the 2–4 replicates
with error range equal to the standard deviation. Most peptide sequences listed in column 2 were identified using MS/MS sequence information, in addition to several
other criteria (mass within 0.005% of a known peptide, and the correct number of isotopic tags incorporated and charge state based on amino acid composition; see
Materials and Methods) . Peptides surrounded by parentheses are tentatively identified by matches to known peptides.
doi:10.1371/journal.pone.0028152.t001
Figure 7. Comparison of food intake in mice injected with proSAAS-derived peptides. Mice do not show a significant peptide-induced
change in food intake measured 1 hour, 2 hours, or 14 hours after the injection of either saline or the proSAAS-derived peptides: PEN, big LEN, little
SAAS, or a combination of PEN and big LEN. Altogether 18 mice were cannulated and after recovery from surgery, injected with either 10 mgo f
peptide in saline or with saline alone. After 3–7 days of recovery, the mice were re-tested with the saline and peptide groups switched so that over
the course of the study, each mouse received at least one control saline injection and injection of at least one of the different peptides. Error bars
show standard error of the mean for saline (n=37); PEN (n=15); big LEN (n=15); little SAAS (n=8); and the combination of PEN and big LEN (n=16).
doi:10.1371/journal.pone.0028152.g007
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hypothalamic slices from rats. Putative neurosecretory parvocel-
lular neurons were identified on the basis of their visualized
position within the PVN and on electrophysiological criteria
[29,30]. The peptide big LEN (1 mM) applied in the bath
perfusion had no effect on the membrane holding current required
to clamp the cell at 260 mV (baseline: 221.166.1 pA; big LEN
25.668.2 pA; p=0.51; n=9) or on the mean input resistance
(baseline: 723.3676.6 MV; big LEN 708.2687.8 MV; p=0.77;
n=9). These results suggest that big LEN has no direct
postsynaptic effect on the PVN parvocellular neuron passive
properties. Big LEN (1 mM) application did, however, have an
inhibitory effect on excitatory synaptic activity in PVN parvocel-
lular neurons, causing a significant decrease in the frequency of
glutamate-mediated spontaneous excitatory postsynaptic currents
(EPSCs) (to 70.564.9% of baseline; p,0.05; n=9 cells), but not
on the EPSC amplitude (96.762.4% of baseline; p=0.88) or decay
time (99.463.2% of baseline; p=0.55) (Figure 9). The big LEN-
induced suppression of excitatory synaptic inputs to PVN
parvocellular neurons had a rapid onset (3–5 min) and was
reversible after 20–30 min of washout of the peptide. Blocking
spike-dependent neurotransmitter release did not inhibit the effect
of big LEN on glutamatergic inputs, as big LEN induced a
decrease in spontaneous EPSC frequency in the presence of the
voltage-gated sodium channel blocker tetrodotoxin (0.5 mM) to
69.864.2% of baseline (n=6; p,0.05) (Figure 9D). This suggested
that big LEN suppressed excitatory synaptic inputs to PVN
parvocellular neurons by acting at presynaptic receptors on
glutamatergic terminals.
We next investigated the molecular mechanisms of the big LEN
effect in PVN parvocellular neurons by testing for a postsynaptic G
protein dependence. The G protein blocker GDP-b-S (0.5–1 mM)
was applied through the patch pipette to block postsynaptic G
protein activity in the recorded cells. Blocking postsynaptic G
protein activity with GDP-b-S inhibited the decrease in EPSC
frequency induced by big LEN (94.563.3% of baseline; p=0.07;
n=12). Since GDP-b-S is membrane impermeant and its actions
are restricted to the postsynaptic cell, this indicated that the effect
of big LEN on glutamate release was dependent on postsynaptic G
protein activity in the parvocellular neurons, and implicates the
involvement of a retrograde synaptic messenger that suppresses
presynaptic glutamate release.
Discussion
The major finding of the present study is that proSAAS-derived
peptides have properties consistent with a function as neuropep-
tides involved in the regulation of feeding. One of the findings that
support this role for proSAAS-derived peptides is their general
colocalization with NPY. This conclusion was supported by
immunofluorescence with antisera to several proSAAS-derived
peptides and two different approaches to visualize NPY-positive
neurons; an antibody to NPY peptide, and the GFP reporter
under the control of the NPY gene promoter. There was no
observed colocalization of proSAAS-derived peptides with a-
MSH, an important anorexigenic peptide. This supports an
orexigenic role for the proSAAS-derived peptides, which fits with
previous studies on transgenic mice overexpressing proSAAS,
which were slightly overweight, and proSAAS knock-out mice,
which showed reduced body weight when male mice were
examined [18,19]. NPY is a major orexigenic neuropeptide,
which transits the regulated secretory pathway and is secreted in
response to signals from the body (ghrelin, amylin, vagus nerve
signals, etc). NPY impinges upon receptors found on second order
neurons in the PVN, the dorsomedial hypothalamus (DMH), and
the LH [31]. ProSAAS-derived peptides which colocalize with
NPY in many neurons should therefore be co-released onto the
NPY-target neurons. While the NPY, big LEN and PEN peptides
do not colocalize completely, this is consistent with their
processing. NPY is processed from its precursor at a Lys-Arg site,
while most of the processing of the proSAAS peptides occurs at
either Arg-Arg or single Arg sites [11,32]. The prohormone
convertases show overlapping but distinct substrate specificities,
which would explain why certain neurons with specific cohorts of
Figure 8. Comparison of food intake in mice injected with purified antibodies directed against proSAAS-derived peptides.
Altogether, 18 mice were cannulated and in each experiment the mice were injected with either saline, control antibody (Cont Ab), or one of the
antibodies directed against proSAAS-derived peptides, and food intake was measured 1 hour, 2 hours, and 14 hours after the injection. The antibody
to PEN significantly reduced food intake at all time points examined. The antibody to big LEN showed a significant decrease in food intake after 1 and
2 hours, but not after 14 hours. In contrast, the antibody to little LEN did not significantly affect food intake at any time point examined, and the
antibody to little SAAS showed a slight increase after 1 hour, but not at the other time points. Error bars show the standard error of the mean; saline
(n=21); control Ab (n=19); PEN Ab (n=8); big LEN Ab (n=20); little LEN Ab (n=10); little SAAS Ab (n=8). *, p,0.05, **, p,0.01, ***, p,0.001 relative
to control Ab, using Student’s two-tailed t-test.
doi:10.1371/journal.pone.0028152.g008
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proSAAS-derived peptides, while others may process only one set
of peptides or the other [33]. The punctate vesicular pattern of
PEN and big LEN supports the hypothesis that these peptides are
processed and released from the regulated secretory system,
consistent with previous results finding that proSAAS expressed in
a mouse corticotrophic cell line was secreted via the regulated
pathway [11] and that proSAAS-derived peptides were released
from cultured hypothalamic slices [34].
Although the distribution of proSAAS mRNA was found to be
highest in the arcuate nucleus when analyzed by in situ
hybridization in a previous study from our group [11] and in
the Allen Mouse Brain Atlas (Figure S1), high levels of proSAAS
mRNA expression are found in other brain regions such as the
PVN, LH, suprachiasmatic nucleus, bed nucleus of the stria
terminalis, medial preoptic area, paraventricular thalamus,
piriform cortex, and multiple areas of the amygdala and
hippocampus. Quantitative real-time PCR of proSAAS mRNA
confirmed that MBH had the highest levels, although levels in
PVN and LH were only slightly lower than MBH. Analysis of the
same RNA samples showed very high levels of proNPY mRNA in
the MBH and much lower levels in the other regions measured,
which fits well with the Allen Mouse Brain Atlas (Figure 1), the
observed distribution using the NPY antibody (Figure 2), the
expression of GFP under the NPY gene promoter (Figure 3) and
previous studies [35]. While the hypothalamic distribution of
proSAAS mRNA is consistent with an orexigenic role for the
proSAAS-derived peptides, the broader distribution in non-
orexigenic neurons supports a potential role for proSAAS-derived
peptides in other behaviors. For example, the proSAAS KO mice
were found to show behavior consistent with elevated anxiety
when placed in an open field [19].
Previous studies have shown an increase in proSAAS-derived
peptide levels in the whole hypothalamus of the Cpe
fat/fat mouse
after a 48 hour fast using the quantitative peptidomics technique
[21,36]. These previous studies however did not find up-regulation
Figure 9. Big LEN suppresses excitatory synaptic input to PVN parvocellular neurons via the release of a retrograde messenger. A.
Whole-cell patch clamp recording of spontaneous synaptic currents in a parvocellular neuroendocrine cell in the PVN in the absence (Control) and
presence of big LEN (Big LEN). Big LEN (1 mM) caused a decrease in the frequency of negative synaptic currents, which are EPSCs mediated by
glutamate release. B. Cumulative frequency plots of EPSC interevent intervals and EPSC amplitudes taken from the recording shown in A. Big LEN
caused a shift toward longer interevent intervals, indicative of a decrease in EPSC frequency, but had no effect on the cumulative amplitude
distribution. C. Mean frequency, amplitude and decay time of EPSCs in big LEN as a percentage of control measures. Big LEN (1 mM) decreased the
frequency of EPSCs, but had no effect on EPSC amplitude or decay time (n=9), suggesting a presynaptic suppression of glutamate release, but no
effect on postsynaptic glutamate sensitivity. D. The effect of big LEN was maintained in TTX, indicating that the effect was action potential
independent, but was blocked by an inhibitor of G protein activity (GDP-b-S) applied via the patch pipette into the postsynaptic cell, suggesting that
the effect is mediated by the activation of a postsynaptic G protein-coupled receptor and release of a retrograde messenger.
doi:10.1371/journal.pone.0028152.g009
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Northern blot. Therefore, one aim of the present study was to
characterize proNPY and proSAAS mRNA regulation in specific
subhypothalamic brain regions of the mouse hypothalamus upon
fasting for 48 hours. ProNPY mRNA levels showed significant
up-regulation with fasting specifically in the MBH, which concurs
with previous studies examining the regulation of proNPY
mRNA in the arcuate nucleus of rats and mice following a two
day fast [28,37,38,39]. ProSAAS mRNA was not significantly
upregulated by fasting in any of the hypothalamic regions
analyzed, and was even slightly decreased in the MBH. The
increase in proSAAS-derived peptide levels observed in Cpe
fat/fat
mouse hypothalamus after a 48-hour fast in the previous
experiments is therefore likely to be regulated at the translational
or post-translational level. Furthermore, while a 2-day fast was
previously found to increase several proSAAS-derived peptides in
Cpe
fat/fat mouse hypothalamus, neither a 1- nor a 2-day fast was
found in the present study to alter the major proSAAS-derived
peptides detected in wild-type mouse hypothalamus. This is
consistent with the absence of a change in proSAAS mRNA levels
upon fasting in most hypothalamic regions of wild-type animals,
and suggests a complex regulatory difference between wild-type
and Cpe
fat/fat animals. ProSAAS mRNA levels in the MBH of the
Cpe
fat/fat mice were significantly lower than in the wild-type mice.
There was also a decrease in the level of proNPY mRNA in the
MBH of Cpe
fat/fat mice relative to wild-type mice, though it did
not reach statistical significance. It is possible that these changes
are secondary to the animals’ obesity, due perhaps to effects of
leptin or other peripheral signals on proNPY and proSAAS
expression.
It has been previously shown that intracerebroventricular
administration of NPY and some other neuropeptides can acutely
affect food intake in rodents [23]. Intracerebroventricular injection
of several proSAAS-derived peptides was performed to assess their
effect on acute feeding. None of these peptides was able to elicit an
acute effect on feeding in wild-type mice. This does not necessarily
mean, however, that these peptides are not involved in feeding or
bodyweight regulation because the injected peptides may not be
stable; there are a number of extracellular peptidases that rapidly
degrade many different peptides. In previous peptidomic studies,
many small proSAAS-derived peptides have been detected which
result from cleavages at nonbasic sites [33,40]. These smaller
peptides are presumably generated by the action of extracellular
proteases, which would mean that proSAAS-derived peptides are
substrates of these enzymes. Introcerebroventricluar injection of
angiotensin II was preformed to verify proper cannulation, and as
all mice responded by increased drinking behavior, the injection
coordinates and technique are unlikely to be the explanation for
the lack of response to proSAAS derived peptides. Thus, a second
approach was used; blocking peptide function by the injection of
antibodies. Previous studies have used antibodies to block the
biological effect of neuropeptides [24]. Injection of the purified big
LEN and PEN antibodies showed acute effects on food intake
relative to a control antibody and to saline. The decrease in food
intake observed with these antibodies is consistent with the
orexigenic role proposed for the proSAAS peptides, and suggested
by their localization and the phenotypes of knockout and
transgenic animals. In contrast, the other antibodies tested did
not show a consistent change relative to either saline or the control
antibody. Thus, while big LEN appears to affect feeding, little
LEN does not. These two peptides differ in the C-terminal region,
with little LEN being 6 amino acids shorter than big LEN. There
are many examples where the extent of processing of neuropeptide
precursors influences the resulting biological activity [41].
A number of different neuropeptides are known to modulate
neuronal activity through various mechanisms. We tested big
LEN on cells in a brain region influenced by NPY. We postulated
that, because big LEN is colocalized with NPY in many neurons
within the arcuate nucleus, it should also be co-released with
NPY and potentially modulate a neuronal target of NPY
projections, the parvocellular neuroendocrine cells in the PVN
[42]. The finding that big LEN suppressed glutamate release onto
PVN parvocellular neurons is further evidence that this peptide is
functional as a neuropeptide. Furthermore, the postsynaptic G
protein dependence and the TTX insensitivity of the effect
suggest that big LEN inhibits glutamate release via postsynaptic
G protein activation, suggesting a postsynaptic site of peptide
action and involvement of a retrograde messenger. Taken
together, our data suggest that the peptide big LEN suppresses
excitatory synaptic input to PVN parvocellular neurons by
activating a G protein-coupled receptor on the PVN parvocel-
lular neurons and stimulating the release of a retrograde
messenger, which acts on presynaptic terminals to suppress
glutamate release. Thus, big LEN has the cellular distribution
and functional properties to be considered a neuropeptide
involved in the regulation of food intake.
Materials and Methods
Reagents
Unless indicated, reagents were obtained from Sigma-Aldrich
(St.Louis, MO, USA). Big LEN and PEN antisera used in these
experiments were previously generated in rabbit [43]. The cross
reactivity of these antisera with other proSAAS-derived peptides
has been previously reported [44]. A chicken antiserum to the
peptide PEN-LEN was also previously generated and character-
ized [14]. Commercially available anti-NPY (Phoenix Pharma-
ceuticals, Burlingame, CA, USA) and anti-a-MSH (Millipore,
Billerica, MA, USA) antisera were used. Little LEN antiserum was
the generous gift of Dr. Iris Lindberg (Dept. Anatomy and
Neurobiology, University of Maryland-Baltimore, MD, USA).
Animals
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME)
were maintained in individual cages on a 12-h light/dark cycle.
NPY-GFP mice (B6.FVB-Tg(Npy-hrGFP)1Lowl/J) mice were the
gift of Dr. Clemence Blouet and Dr. Gary Schwartz (Albert
Einstein College of Medicine), and were originally obtained from
Jackson Laboratory (Bar Harbor, ME). Mice were 8–10 weeks of
age at the start of all experiments. All efforts were made to
minimize the suffering and the number of animals used. The
experiments were approved by the Institutional Animal Care and
Use Committee and the Institute for Animal Studies of Albert
Einstein College of Medicine (protocol number 20090305).
Tissue preparation for immunohistochemistry
Mice were anaesthetized using diethyl ether and perfused
transcardially through the ascending aorta with 4% buffered
paraformaldehyde. Brains were postfixed overnight in 4%
buffered paraformaldehyde at 4uC, subsequently dehydrated in
30% sucrose in phosphate buffered saline overnight, embedded in
Tissue-Tek Optimal Cutting Temperature compound (Sakura
Finetek, Torrance, CA, USA) and frozen in isopentane (Fisher
Scientific Hampton, NH, USA) at 250uC and stored at 270uC
until cutting. Coronal sections of 14 mm were cut on a sliding
microtome in the region of the arcuate nucleus of the
hypothalamus and thaw mounted onto Superfrost Plus microscope
slides (Fisher Scientific, Hampton, NH, USA).
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Sections on slides were washed with PBS, then blocked for
2 hours at room temperature in 5% bovine serum albumin (BSA)
in PBS containing 0.5% Triton X-100. Slides were then incubated
for 24 hours at 4uC with either chicken anti-PEN-LEN (1:20,000),
rabbit anti-big LEN #85 (1:10,000), rabbit anti-PEN #142
(1:10,000), rabbit anti-NPY (1:200, Phoenix Pharmaceuticals,
Burlingame, CA, USA) or sheep anti-a-MSH (1:5000, Millipore,
Billerica, MA, USA) in 5% BSA in PBS with 0.5% Triton X-100.
After washing with PBS containing 0.2% Tween-20, secondary
Cy3- and Cy2-conjugated antibodies (Jackson Immunoresearch,
West Grobe, PA, USA) were applied. After overnight incubation
at 4uC, the sections were washed and mounted in antifade reagent
containing 4,6- diamidino-2-phenylindole (DAPI; Invitrogen,
Carlsbad, CA, USA). To control for non-specific staining,
preimmune serum from each of the animals used for the
proSAAS-derived peptide antisera were applied to adjacent
sections at the same dilutions as the antisera (Figure S2).
Additional controls were performed by preincubating the antisera
with the appropriate peptide prior to incubation with the tissue
(Figure S2).
RNA extraction
Male mice between 9 and 10 weeks old were fasted or fed ad
libitum for 48 hours prior to sacrifice by cervical dislocation and
brains were excised. Three mice were used for each of the fasted
and fed conditions. Brains were cut into 1.5 mm coronal sections.
The mediobasal hypothalamus, the bilateral lateral hypothalamus,
and the paraventricular nucleus were dissected from the section
containing the arcuate nucleus, bregma 21.3 mm to 22.8 [45]
Brain regions were immediately frozen and stored at 270uC until
extraction. RNA extraction was performed using 500 mL Qiazol
(Qiagen) reagent per brain region. Tissues were sonicated for ten
pulses (50% duty cycle, level 3, one second per pulse). Qiagen
Lipid RNeasy Mini RNA extraction kit (Qiagen) was used
according to manufacturer’s directions, and RNA was eluted in
20 mL of RNAse free water. cDNA was then generated using the
Superscript III First Strand Synthesis System for RTPCR
(Invitrogen). Random hexamer primers were used with 400 ng
extracted RNA per brain region.
Quantitative real-time PCR (qRTPCR)
qRTPCR was performed using the following primer sets
(Invitrogen, Carlsbad, CA, USA): proNPY (Forward 59-
GTTTGGGCATTCTGGCTGAGGG, Reverse 59-TGTCTCA-
GGGCTGGATCTCTTGC), proSAAS (Forward 59-ATTT-
TGGTGCTGCTGCTCTT, Reverse 59-GGAGTGCTCGTCT-
CAACCA) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH: Forward 59-AGATTGTTGCCATCAACGAC, Re-
verse 59-TTGACTGTGCCGTTGAATTT). All primer sets were
intron-spanning and were verified by cDNA transcript length by
amplification using SuperScript III One-Step RT-PCR System
with Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA,
USA) and gel electrophoresis. cDNA generated by first strand
synthesis was used to quantify RNA levels by qRTPCR using
Power SYBR Green PCR master mix (Applied Biosystems,
Warrington, UK) in 384 well plates on an ABI 7900HT Fast
Real-time PCR system (Applied Biosystems, Warrington, UK)
using a SYBR 3-step protocol at the Albert Einstein College of
Medicine genomics core facility. Data analysis was performed
using SDS software (Version 2.1, Applied Biosystems, Warrington,
UK). Fold change in RNA was calculated from qRTPCR results
using the DDCT method. To calculate the levels of proSAAS and
proNPY mRNA among the brain regions analyzed, the levels in
the PVN and the LH were compared to the levels in the MBH,
which was set as one. To calculate the difference in proSAAS and
proNPY mRNA levels between wild-type and Cpe
fat/fat mice, the
level of mRNA in each wild-type brain region was set as one, and
levels in the Cpe
fat/fat mice were compared to those levels. In the
comparison of the fed and fasted wild-type mice, the level of each
mRNA in the fed mice brain regions was set at one, and the
mRNA levels in the fasted mice were compared to those levels.
Significance of changes was calculated using the two-tailed
Student’s t-test.
Peptidomic analysis of hypothalamic peptides under
variously fed and fasted conditions
Thirty two male mice were split into four groups of eight mice
each. Each group of mice was kept on a separate feeding schedule.
These feeding schedules consisted of a 24 hour fast, a 48 hour fast,
and two groups that were fed ad libitum during the experimental
period. All mice were 7–8 weeks old at the time of the
experiments. Mice were sacrificed and tissues were collected as
previously described [33]. Tissue was frozen in dry ice and stored
at 270uC until analysis. Tissue was extracted and labeled as as
previously described [46,47].
To detect and quantify the labeled peptides from fasted and fed
mouse hypothalami, liquid chromatography and tandem mass
spectrometery (LC/MS/MS) was performed on a Waters Q-TOF
- Ultima Mass Spectrometer (Micromass, Manchester, UK) as
previously described [48]. The most intense ion in each MS survey
scan was fragmented to generate MS/MS spectra. Peptides were
identified as previously described [33,47,49]. To reduce the
number of false-positives, all Mascot hits were manually
interpreted as previously described (Berti et al. 2009;Morano et
al. 2008;Zhang et al. 2008). Quantitation was performed as
previously described [20,47]. In brief, the peak intensity for the
monoisotopic peak and the peak containing one
13C atom were
averaged. In spectra with overlapping peaks in which the signals
with multiple
13C atoms extended into the range of the next
TMAB tag, the isotopic distribution of the peptide was calculated
and the contribution from the
13C-containing peaks subtracted, as
described [47]. Each LC/MS run contained tissue extract from a
group of 24 hour-fasted mice, a group of 48 hour-fasted mice, and
two groups of mice fed ab libitum. The relative peak intensity for
each of these groups was determined for each of the three
replicates, and the ratios of these replicates were averaged.
Antibody purification
Protein A agarose columns (Invitrogen, Carlsbad, CA, USA)
were used for purification of antibodies prior to icv injection
according to manufacturers’ instructions. The IgG concentration
of each elute was determined using a spectrophotometer.
Cannulation
Mice were anaesthetized using isoflurane and fixed by ear bars
in a stereotactic apparatus. The top of the mouse head was shaved
and cleaned using sterile cotton swabs, betadine solution and
isopropyl alcohol solution. Once dry, a small section of the scalp
was removed with scissors. The exposed skull was then cleaned
with sterile saline followed by 30% hydrogen peroxide solution.
After drilling a hole in the skull, the guide cannula (Plastics One,
Roanoke VA) was inserted at bregma 21.82 mm to a depth of
bregma 25 mm. The guide cannula was held in place using
metals screws and dental cement, and occluded to prevent
clogging using a 5.5 mm obturator. Mice were allowed to heal
for 7–10 days before injections were performed.
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Mice were initially injected with 50 ng angiotensin II in 2 mL
sterile saline and observed for drinking response to verify
cannulation into the third ventricle. All mice showed a marked
stimulation of water consumption following the angiotensin II
injection.
In subsequent studies, mice were fasted for 8 hours prior to
lights out. For injection of antibodies to proSAAS-derived peptides
or a control antibody generated against a Drosophila antigen, 5 mg
of purified antibody in 2 ml of injectate was infused by hand at a
rate of 0.5 ml/minute, using a 5 ml Hamilton syringe (Hamilton
Company, Reno NV) attached by PE20 tubing, 0.38 mm inside
diameter (Plastics 1, Roanoke VA) to an injector cannula (Plastics
1) which protruded 0.5 mm below the bottom of the guide
cannula. For injection of proSAAS peptides, 10 mg of peptide in
2 ml sterile saline (or saline alone as a control) was infused at
0.5 ml/minute. After injection, the obturator was replaced, the
mouse was returned to his home cage, and food was provided. In a
typical experiment, 6–8 mice were injected with a single peptide or
antibody to a proSAAS-derived peptide, and an equal number
received the control saline or control antibody injection. All mice
received injections before lights out, timed so that the food
measurements were performed during the dark cycle. The
quantity of food remaining was measured one hour, two hours,
and 14 hours post-injection. After 4–7 days of recovery, the
experiment was repeated with groups switched so that all mice
received both control and big LEN antibodies and at least one of
the PEN, little LEN or little SAAS antibodies.
Tissue preparation for patch-clamp electrophysiology
Male Wistar rats (4–6 weeks old, Harlan Laboratories,
Indianapolis, IN) were used in these experiments according to a
protocol approved by the Tulane University Institutional Animal
Care and Use Committee. Rats were decapitated under ketamine-
xylazine anesthesia and the brain was quickly removed from the
skull. Two to three 300- mm coronal hypothalamic slices
containing the bilateral paraventricular nuclei were sectioned on
a vibratome (Vibratome, St. Louis, MO) in ice-cold artificial
cerebral spinal fluid (aCSF), in which NaCl was replaced by an
equimolar concentration of sucrose to improve neuronal viability.
The standard aCSF contained 140 mM NaCl, 3 mM KCl,
1.3 mM MgSO4, 1.4 mM NaH2PO4, 2.4 mM CaCl2,1 1m M
glucose, and 5 mM HEPES, bubbled with 100% O2. The slices
were bisected at the third ventricle, and each half slice was
submerged in a holding chamber in oxygenated aCSF at room
temperature, where it was allowed to equilibrate for 1.5–2 h
before being transferred to the recording chamber.
Patch-clamp recordings
After transfer to the recording chamber, slices were allowed to
equilibrate for .15 min and maintained at a temperature of 32–
34uC throughout recordings. Paraventricular nucleus medial
parvocellular neurons were targeted by direct visualization under
infrared illumination and differential interference contrast optics.
Patch electrodes were pulled to a tip resistance of 3–4 MV on a
Flaming-Brown horizontal pipette puller (P-97, Sutter Instru-
ments, Novato, CA). The internal recording solution contained
120 mM K-gluconate, 10 mM KCl, 1 mM NaCl, 1 mM MgCl2,
1 mM CaCl2, 10 mM EGTA, 2 mM Mg-ATP, 0.3 mM Na-GTP,
and 10 mM HEPES. Cells with unstable input resistance or series
resistance were discarded. All recordings were performed in
voltage clamp mode using a Multiclamp 700A amplifier and
pCLAMP 9 software (Molecular Devices, Sunnyvale, CA). Data
were low-pass filtered at 2 kHz, digitized at 5 kHz and recorded
for off-line analysis. In a subset of neurons, tetrodotoxin (TTX,
1 mM) was added to the aCSF to block spike-mediated transmitter
release. Postsynaptic currents were analyzed for changes in
frequency, amplitude and decay time (defined as the time from
peak to 63% decay) using the Minianalysis 6.0 program
(Synaptosoft Inc., Decatur, GA).
Electrophysiological data analysis
All data are expressed as means 6 standard errors. Statistical
comparisons of electrophysiological data were performed using the
Student’s paired t-test for within-group cell comparisons, the
Student’s unpaired t-test for between-group comparisons. P values
of ,0.05 were considered significant for all comparisons.
Supporting Information
Figure S1 ProSAAS, proSAAS-derived peptides, and the
distribution of proSAAS mRNA in mouse brain.
(PDF)
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